Lo Y.TSEN-FANG TSAI2020-10-222020-10-2220190007-0963https://www.scopus.com/inward/record.uri?eid=2-s2.0-85070869912&doi=10.1111%2fbjd.18174&partnerID=40&md5=ffc335e80d02ada873b616f11ebe9071https://scholars.lib.ntu.edu.tw/handle/123456789/517537[SDGs]SDG3cyclosporine; etretin; ixekizumab; methotrexate; secukinumab; dermatological agent; ixekizumab; monoclonal antibody; secukinumab; adult; body surface; chronic disease; clinical article; drug effect; drug safety; erythrodermic psoriasis; female; human; injection site reaction; injection site swelling; Letter; male; medical history; medical record review; middle aged; monotherapy; personal experience; prescription; priority journal; Psoriasis Area and Severity Index; retrospective study; treatment response; drug resistance; drug substitution; erythroderma; immunology; psoriasis; severity of illness index; treatment outcome; Adult; Antibodies, Monoclonal, Humanized; Dermatitis, Exfoliative; Dermatologic Agents; Drug Resistance; Drug Substitution; Female; Humans; Male; Middle Aged; Psoriasis; Retrospective Studies; Severity of Illness Index; Treatment OutcomeClinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case seriesletter10.1111/bjd.18174311458062-s2.0-85070869912